As June 1 Deadline Looms, Drug Manufacturers and Feds Make Their Case in New Jersey Federal Court

Drug makers Novo Nordisk and Sanofi and the federal government filed briefs Tuesday and Wednesday in federal district court in New Jersey in the two manufacturers’ separate challenges to the contract pharmacy requirements.
Drug makers Novo Nordisk and Sanofi and the federal government filed briefs Tuesday and Wednesday in federal district court in New Jersey in those two manufacturers’ separate challenges to the contract pharmacy requirements.

Please Login or

Read More »

Key Hearings Today in AstraZeneca and Lilly’s 340B Contract Pharmacy Lawsuits

AstraZeneca and Eli Lilly will be before federal district judges today seeking to stop enforcement of 340B contract pharmacy requirements they oppose.
Federal judges in Delaware and Indiana will hear arguments today in drug manufacturers’ AstraZeneca and Eli Lilly’s separate lawsuits challenging the 340B contract pharmacy requirements.

Please Login or Become a Paid Subscriber to View this Content

Read More »

PhRMA Sues to Block Medicaid Best Price Change

PhRMA is challenging a CMS Medicaid prescription drug best price rule that it says "will harm patients and manufacturers alike." | Shutterstock
Pharmaceutical Research and Manufacturers of America (PhRMA) has asked a federal judge to invalidate a federal regulation that would require drug makers, starting in January 2023, to include the full value of patient financial assistance in their Medicaid best price
Read More »

New Developments in 340B Contract Pharmacy Lawsuits

Federal judges yesterday issued orders in four lawsuits over 340B program contract pharmacy policy.
Federal courts in Delaware, Indiana, and New Jersey yesterday issued orders related to the federal government’s May 17 demand to six drug manufacturers to immediately resume unrestricted 340B pricing on drugs shipped to contract pharmacies. The government asked AstraZeneca, Eli
Read More »

BREAKING: Developments in Multiple 340B Contract Pharmacy Lawsuits

Eli Lilly and Sanofi yesterday filed court papers in response to HRSA's 340B contract cease and desist letters. Novo Nordisk is expected to follow suit. There could be a decision on AstraZeneca's motions as soon as tonight. | Shutterstock
Drug manufacturers Eli Lilly and Sanofi late yesterday asked federal judges for temporary protection from federal health agency orders to immediately resume offering 340B pricing on drugs shipped to contract pharmacies. Drug maker Novo Nordisk is expected to seek similar
Read More »

BREAKING: Developments in AstraZeneca’s 340B Lawsuit

A federal district judge is considering AstraZeneca’s emergency motion yesterday for a stay in its lawsuit over the government’s efforts to compel it to resume 340B pricing on drugs dispensed by contract pharmacies.
A federal district judge in Wilmington, Del., this morning gave the federal government until 11:00 a.m. Eastern tomorrow to respond to AstraZeneca’s emergency motion yesterday for a stay in its lawsuit over the government’s efforts to compel it to resume
Read More »

Drugmakers Show No Sign So Far of Giving in to HRSA on 340B Contract Pharmacy

So far, drug manufacturers have shown no sign of obeying HRSA's order to resume 340B pricing without regard to how drugs are dispensed. | Shutterstock
Six drug companies have shown no sign so far of acquiescing to the federal government’s order on Monday to immediately resume 340B pricing on their products dispensed by contract pharmacies.

Please Login or Become a Paid

Read More »

Health Centers, HIV/AIDS Clinics, and Feds Agree on Keeping Stays in Place in 340B Lawsuits

In separate status reports to a federal judge last night, health centers and the government, and HIV/AIDS clinics and the government, agreed to keep stays in place in lawsuits involving 340B contract pharmacy. | Shutterstock
The National Association of Community Health Centers (NACHC) and the U.S. Justice Department (DOJ) last night proposed that a federal district judge should maintain the stay in NACHC’s suit against the government stemming from drug manufacturers’ denials of 340B pricing
Read More »

HHS Asks U.S. Supreme Court to Reject 340B Hospital Request to Hear Medicare Part B Case

HHS has asked the U.S. Supreme Court to decline taking up 340B hospital suit on Medicare Part B reimbursement.
While 340B hospitals eagerly await to see the Biden administration’s plans for Medicare Part B reimbursement, the U.S. Department of Health and Human Services (HHS) last night asked the U.S. Supreme Court to reject an effort by hospital groups to
Read More »

DOJ Cites 1996 HRSA Letter to PhRMA in Request to Dismiss Novo Nordisk’s 340B Contract Pharmacy Suit

DOJ says Novo Nordisk’s claim that HHS's 340B contract pharmacy advisory opinion would make it break the law “is mere legerdemain.”
Novo Nordisk’s claim that a federal legal advisory opinion on 340B contract pharmacy would make it unlawfully transfer its drugs to ineligible pharmacies and ineligible patients “is mere legerdemain” (slight of hand), government lawyers for U.S. Health and Human Services
Read More »